Mechanisms of angiogenesis: Clinical and therapeutic applications;Les mécanismes de l'angiogenèse. Applications médicales et thérapeutiques

Revue de Medecine Interne

Volumn 22, Issue 11, 2001, Pages 1064-1082

  Couffinhal, T ^a,b   Dufourcq, P ^b   Daret, D ^b   Duplaa C ^b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Angiogenesis; Endothelial cell; Myocardial schemia; Smooth muscle cell; Tumor

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAP JUNCTION PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE CELL ADHESION MOLECULE; PROSTAGLANDIN SYNTHASE; SELECTIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; COLLATERAL CIRCULATION; ENDOTHELIUM; HEART MUSCLE ISCHEMIA; METASTASIS; REVIEW; SMOOTH MUSCLE FIBER; SOLID TUMOR;

EID: 18544391853     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(01)00472-6     Document Type: Short Survey

References (86)

1. Tumor angiogenesis: Therapeutic implications
2. Angiogenesis
3. Clinical applications of research on angiogenesis
4. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model
5. Mechanisms of angiogenesis
6. Pericytes in the microvasculature
7. Vascular permeability factor (VPF, VEGF) in tumor biology
8. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, while hypoxia upregulates VEGF expression only
9. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
10. Angiogenesis is coming of age
11. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atheroclerotic human arteries
12. Vascular endothelial growth factor
13. A mouse model of angiogenesis
14. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction
15. Structural and functional specificity of FGF receptors
16. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischernic region of the heart
17. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
18. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
19. Increased vascularizafion in mice overexpressing angiopoietin-1
20. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
21. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2
22. Role of vascular endothelial growth factor in the regulation of angiogenesis
23. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
24. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
25. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins
26. Developmental biology. Controlling the cellular brakes
27. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
28. Isolation of endothelial cells and their progenitor cells from human peripheral blood
29. Angiopoietin-1 is an antipermeability and anti-inflammatory agent In vitro and targets cell junctions
30. Angiopoietin-1 protects the adult vasculature against plasma leakage
31. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
32. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
33. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact
34. Requirement of vascular integrin alphanubeta3 for angiogenesis
35. Mechanisms of angiogenesis and arteriogenesis
36. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
37. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
38. Integrin avB3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
39. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth
40. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression
41. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis
42. Molecular mechanisms of coronary collateral vessel growth
43. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
44. Hypoxia-inducible factor 1: From molecular biology to cardiopulmonary physiology
45. Role of HIF-lalpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
46. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: Evidence against a regulatory role for Src kinase
47. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
48. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/-mice
49. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
50. Angiogenesis and tumor metastasis
51. Small molecule inhibitors of tumorpromoted angiogenesis, including protein tyrosine kinase inhibitors
52. Tumor angiogenesis: Past, present and the near future
53. Angiogenesis in cancer and other diseases
54. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
55. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α V Β 3
56. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor
57. Angiostatin induces and sustains dormancy of human primary tumors in mice
58. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
59. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470
60. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts
61. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
62. Changes in estimated coronary risk in the 1980s: Data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases
63. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease
64. Incidence, clinical characteristics, and short-term prognosis of angina pectoris
65. Coronary heart disease: Overview
66. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure
67. Angina reassessed: Pain or protector?
68. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium
69. Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium
70. Importance of diagnosing hibernating myocardium: How and in whom?
71. Multifactorial basis for coronary collateralization: A complex adaptive response to ischemia
72. Stable angina: Drugs, angioplasty or surgery?
73. Advances in coronary angioplasty
74. Long term prognosis after CABG in relation to preoperative left ventricular ejection fraction
75. Results of revascularization in patients with severe left ventricular dysfunction
76. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients
77. The importance of completeness of revascularization during long-term follow-up after coronary artery operations
78. Induction of neoangiogenesis in ischemic myocardium by human growth factors
79. Constitutive expression of phVEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
80. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease
81. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
82. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease
83. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
84. Left ventricular electromechanical mapping to assess efficacy of phVEG (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia
85. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
86. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells